Stocks · Health care · Biological Products, (No Diagnostic Substances)

Kalaris Therapeutics, Inc.

KLRS Clue Score19

United States Fiscal year ends December CIK 0001754068 Results filed 11 Aug 2026

Add to watchlist

What the insiders did Net buying

Individual transactions

Insider

Date

Role

Action

Price

Amount

Srinivas Akkaraju

20 May 2026

Director

Buy indirect

244,300

$4.83

$1.18M

Srinivas Akkaraju

18 Dec 2025

Director

Buy indirect

479,847

$10.42

$5.00M

Gilead Sciences, Inc.

27 Jun 2023

10% owner

Buy

2,930,870

$3.75

$10.99M

Jeffrey S Bornstein

26 Apr 2022

Director

Buy

5,000

$4.64

$23.20K

Jeffrey S Bornstein

10 Feb 2022

Director

Buy

5,000

$8.87

$44.35K

Showing 250 of 349 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 320

Amendments (4/A) skipped 5

Filings about a different issuer 0

Unreadable filings 0

Joint filings 4

Sales on a Rule 10b5-1 plan 29

Sales straight out of an exercise 0

Sales at will 310

Transactions with no price 0

Shares from compensation/vesting 121,627,984

Sales filed before the plan box existed 217

History held since 31 Jul 2020